CARAT SIGNED
Chimeric Antigen Receptors (CARs) for Advanced Therapies
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CARAT project word cloud
Explore the words cloud of the CARAT project. It provides you a very rough idea of what is the project "CARAT" about.
Project "CARAT" data sheet
The following table provides information about the project.
| Coordinator |
MILTENYI BIOTEC GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | http://carat-horizon2020.eu/ |
| Total cost | 5˙989˙158 € |
| EC max contribution | 5˙989˙158 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-PHC-2015-two-stage |
| Funding Scheme | RIA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-01-01 to 2019-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | MILTENYI BIOTEC GMBH | DE (BERGISH GLADBACH) | coordinator | 1˙349˙760.00 |
| 2 | OSPEDALE SAN RAFFAELE SRL | IT (MILANO) | participant | 913˙300.00 |
| 3 | UNIVERSITAETSKLINIKUM FREIBURG | DE (FREIBURG) | participant | 718˙580.00 |
| 4 | BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | DE (LANGEN) | participant | 714˙825.00 |
| 5 | UNIVERSITY COLLEGE LONDON | UK (LONDON) | participant | 660˙398.00 |
| 6 | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE | FR (PARIS) | participant | 646˙770.00 |
| 7 | EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH | DE (ST INGBERT) | participant | 562˙775.00 |
| 8 | TRAKCEL LIMITED | UK (CARDIFF) | participant | 422˙750.00 |
Map
Project objective
Chimeric antigen receptors (CARs) are artificial surface receptors that can be introduced into somatic cells by genetic engineering and that act as recognition molecules like antibodies or T-cell receptors. In this respect, CARs are increasingly used for cellular therapy to redirect T-cells specifically towards killing of cancer cells. Recent success stories of cancer therapy with CAR modified T-cells have raised enormous scientific and public expectations to cure severely ill patients. However, there are still many obstacles to overcome for translation into clinics because the technology for GMP-compliant manufacture of genetically modified cellular products is extremely complex and expensive. Moreover, CAR therapy needs to be improved with respect to off-target activity, safety and potency. Consequently, the envisaged project is overall aiming at a particular technological breakthrough in cellular cancer therapy by delivering a comprehensive CARAT platform explicitly tailored for automated, easy-to-handle and cost-efficient manufacture of CAR-modified ATMP. Specifically, we aim:
(a) to implement unique next-generation cell processing tools like the CliniMACS Prodigy (b) to develop advanced enabling technologies to obtain more effective and safer cellular products by improved gene delivery and innovative CARs design (c) to assemble tools and technologies towards an integrated CARAT process for automated GMP-compliant manufacture of gene-modified T-cells (d) to demonstrate proof-of-concept and regulatory compliance (e) to disseminate broadly applicable, simplified CAR T-cell technologies
In summary, our vision is to overcome current hurdles for translation of cellular therapies and to elevate them to the next level of standard-of-care thus serving patients with so far incurable solid tumours and hematologic malignancies. Thereby, we will empower Europe to become a global leader in the development and commercialisation of CAR T-cell tools and technologies.
Deliverables
| Project website | Websites, patent fillings, videos etc. | 2019-10-14 12:21:24 |
Take a look to the deliverables list in detail: detailed list of CARAT deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Dominik Lock, Nadine Mockel-Tenbrinck, Katharina Drechsel, Carola Barth, Daniela Mauer, Thomas Schaser, Carolin Kolbe, Wael Al Rawashdeh, Janina Brauner, Olaf Hardt, Natali Pflug, Udo Holtick, Peter Borchmann, Mario Assenmacher, Andrew Kaiser Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use published pages: 914-925, ISSN: 1043-0342, DOI: 10.1089/hum.2017.111 |
Human Gene Therapy 28/10 | 2019-10-14 |
| 2017 |
S. A. Haas, V. Dettmer, T. Cathomen Therapeutic genome editing with engineered nucleases published pages: 45-52, ISSN: 0720-9355, DOI: 10.5482/HAMO-16-09-0035 |
Hämostaseologie 37/1 | 2019-10-14 |
| 2017 |
Jessica Hartmann, Martina Schüßlerâ€Lenz, Attilio Bondanza, Christian J Buchholz Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts published pages: e201607485, ISSN: 1757-4676, DOI: 10.15252/emmm.201607485 |
EMBO Molecular Medicine | 2019-10-14 |
| 2017 |
Elisa Peranzoni, Houcine Bougherara, Sarah Barrin, Audrey Mansuet-Lupo, Marco Alifano, Diane Damotte, Emmanuel Donnadieu Ex Vivo Imaging of Resident CD8 T Lymphocytes in Human Lung Tumor Slices Using Confocal Microscopy published pages: , ISSN: 1940-087X, DOI: 10.3791/55709 |
Journal of Visualized Experiments 130 | 2019-10-14 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CARAT" are provided by the European Opendata Portal: CORDIS opendata.